GlaxoSmithKline must do more to convince investors

Manager of the European Fund at SW Mitchell Capital, Stuart Mitchell has £20m invested in GSK, and tells Fund Strategy the firm has gone through a lot of pressure recently and there is still the possibility of it splitting up. Evenlode’s Hugh Yarrow says the consumer division of GSK will perform better and the pharma division of the firm ‘will become more profitable’